{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:20:27Z","timestamp":1789658427423,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11102-021-01188-7","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:08:12Z","timestamp":1632766092000},"page":"978-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-6071","authenticated-orcid":false,"given":"Karan J.","family":"Yagnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L. D.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret","family":"Choby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Peris-Celda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie J.","family":"Van Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"1","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000497746","volume":"109","author":"L Vroonen","year":"2019","unstructured":"Vroonen L, Daly AF, Beckers A (2019) Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109(1):20\u201327. https:\/\/doi.org\/10.1159\/000497746","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1188_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3\u20136. doi:https:\/\/doi.org\/10.1007\/s11102-005-5079-0","journal-title":"Pituitary"},{"issue":"2","key":"1188_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1188_CR4","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721\u20134727. doi:https:\/\/doi.org\/10.1210\/jc.2007-2758","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","volume":"14","author":"J Webster","year":"1996","unstructured":"Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14(4):228\u2013238. https:\/\/doi.org\/10.2165\/00002018-199614040-00003","journal-title":"Drug Saf"},{"issue":"4","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704\u20131711. https:\/\/academic.oup.com\/jcem\/article-abstract\/89\/4\/1704\/2844342","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","volume":"39","author":"J Webster","year":"1993","unstructured":"Webster J, Piscitelli G, Polll A et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol. 1993;39(3):323\u2013329. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/j.1365-2265.1993.tb02372.x","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/13543784.11.6.787","volume":"11","author":"A Colao","year":"2002","unstructured":"Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11(6):787\u2013800. doi:https:\/\/doi.org\/10.1517\/13543784.11.6.787","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1210\/jcem-71-3-682","volume":"71","author":"O Serri","year":"1990","unstructured":"Serri O, Beauregard H, Lesage J et al (1990) Long term treatment with CV 205\u2013502 in patients with prolactin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 71(3):682\u2013687. doi:https:\/\/doi.org\/10.1210\/jcem-71-3-682","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000023180","volume":"49","author":"E Delgrange","year":"1998","unstructured":"Delgrange E, Crabb\u00e9 J, Donckier J (1998) Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 49(5):250\u2013253. doi:https:\/\/doi.org\/10.1159\/000023180","journal-title":"Horm Res"},{"issue":"1","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/a:1026225625897","volume":"6","author":"ME Molitch","year":"2003","unstructured":"Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6(1):19\u201327. doi:https:\/\/doi.org\/10.1023\/a:1026225625897","journal-title":"Pituitary"},{"issue":"1","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","volume":"8","author":"ME Molitch","year":"2005","unstructured":"Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8(1):43\u201352. doi:https:\/\/doi.org\/10.1007\/s11102-005-5085-2","journal-title":"Pituitary"},{"issue":"1","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23(1):27\u201337. doi:https:\/\/doi.org\/10.1007\/s11102-019-00987-3","journal-title":"Pituitary"},{"issue":"1","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109(1):42\u201350. https:\/\/doi.org\/10.1159\/000495775","journal-title":"Neuroendocrinology"},{"issue":"5","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485\u2013534. doi:https:\/\/doi.org\/10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"issue":"5","key":"1188_CR16","first-page":"489","volume":"109","author":"P Bolko","year":"2003","unstructured":"Bolko P, Jasku\u0142a M, Wa\u015bko R, Wo\u0142u\u0144 M, Sowi\u0144ski J (2003) The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Pol Arch Med Wewn 109(5):489\u2013495. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14768178","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci M, Qui\u00f1ones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14(1):68\u201374. doi:https:\/\/doi.org\/10.1007\/s11102-010-0261-4","journal-title":"Pituitary"},{"issue":"6","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/qjmed\/hcs240","volume":"106","author":"P Iglesias","year":"2013","unstructured":"Iglesias P, D\u00edez JJ (2013) Macroprolactinoma: a diagnostic and therapeutic update. QJM 106(6):495\u2013504. doi:https:\/\/doi.org\/10.1093\/qjmed\/hcs240","journal-title":"QJM"},{"issue":"5","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas. J Neurosurg 114(5):1369\u20131379. doi:https:\/\/doi.org\/10.3171\/2010.11.JNS101369","journal-title":"J Neurosurg"},{"issue":"2","key":"1188_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265\u2013273. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.endinu.2019.04.007","volume":"67","author":"M Araujo-Castro","year":"2020","unstructured":"Araujo-Castro M, L\u00f3pez AA, Pardo JA, Kanaan LK, Palacios Garc\u00eda N (2020) Phenotype and resistance patterns of 10 resistant prolactinomas. Endocrinol Diabetes Nutr 67(3):194\u2013204. https:\/\/doi.org\/10.1016\/j.endinu.2019.04.007","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"1","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4158\/EP161446.OR","volume":"23","author":"D Donegan","year":"2017","unstructured":"Donegan D, Atkinson JLD, Jentoft M et al (2017) Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 23(1):37\u201345. https:\/\/doi.org\/10.4158\/EP161446.OR","journal-title":"Endocr Pract"},{"issue":"1","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J, Buslei R, Wallaschofski H et al (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11\u201318. doi:https:\/\/doi.org\/10.1530\/EJE-07-0248","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jocn.2015.06.001","volume":"22","author":"TR Smith","year":"2015","unstructured":"Smith TR, Hulou MM, Huang KT et al (2015) Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22(11):1785\u20131791. doi:https:\/\/doi.org\/10.1016\/j.jocn.2015.06.001","journal-title":"J Clin Neurosci"},{"issue":"5","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166(5):779\u2013786. doi:https:\/\/doi.org\/10.1530\/EJE-11-1000","journal-title":"Eur J Endocrinol"},{"key":"1188_CR26","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1722665","author":"SL Iuliano","year":"2021","unstructured":"Iuliano SL, Bi WL, Laws ER (2021) Changes in the options for management of prolactin secreting pituitary adenomas. J Neurol Surg B Skull BaseDoi. https:\/\/doi.org\/10.1055\/s-0040-1722665","journal-title":"J Neurol Surg B Skull BaseDoi"},{"key":"1188_CR27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz144","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F et al (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336\u2013341. doi:https:\/\/doi.org\/10.1016\/j.ijsu.2010.02.007","journal-title":"Int J Surg"},{"key":"1188_CR29","unstructured":"Ottawa Hospital Research Institute. Accessed April 17 (2021) http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"7454","key":"1188_CR30","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. doi:https:\/\/doi.org\/10.1136\/bmj.328.7454.1490","journal-title":"BMJ"},{"issue":"7414","key":"1188_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. doi:https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"5","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","volume":"158","author":"S Akin","year":"2016","unstructured":"Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M (2016) Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta Neurochir 158(5):933\u2013942. doi:https:\/\/doi.org\/10.1007\/s00701-016-2762-z","journal-title":"Acta Neurochir"},{"issue":"4","key":"1188_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejim.2008.11.012","volume":"20","author":"M Kars","year":"2009","unstructured":"Kars M, Pereira AM, Smit JW, Romijn JA (2009) Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 20(4):387\u2013393. doi:https:\/\/doi.org\/10.1016\/j.ejim.2008.11.012","journal-title":"Eur J Intern Med"},{"issue":"6","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"e14380","DOI":"10.1097\/MD.0000000000014380","volume":"98","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Jin D, Lian W et al (2019) Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old. Medicine 98(6):e14380. doi:https:\/\/doi.org\/10.1097\/MD.0000000000014380","journal-title":"Medicine"},{"issue":"1","key":"1188_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/02688697.2012.714817","volume":"27","author":"FL Vale","year":"2013","unstructured":"Vale FL, Deukmedjian AR, Hann S, Shah V, Morrison AD (2013) Medically treated prolactin-secreting pituitary adenomas: when should we operate? Br J Neurosurg 27(1):56\u201362. doi:https:\/\/doi.org\/10.3109\/02688697.2012.714817","journal-title":"Br J Neurosurg"},{"issue":"5","key":"1188_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea M-L, Petrossians P et al (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167(5):651\u2013662. doi:https:\/\/doi.org\/10.1530\/EJE-12-0236","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1188_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan TB, Iii, Katznelson L (2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 180(1):31\u201340. doi:https:\/\/doi.org\/10.1530\/EJE-18-0682","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1188_CR38","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s12020-014-0369-9","volume":"47","author":"E Bloomgarden","year":"2014","unstructured":"Bloomgarden E, Molitch ME (2014) Surgical treatment of prolactinomas: cons. Endocrine 47(3):730\u2013733. https:\/\/doi.org\/10.1007\/s12020-014-0369-9","journal-title":"Endocrine"},{"key":"1188_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220971","author":"N Mohan","year":"2017","unstructured":"Mohan N, Chia YY, Goh GH, Ting E, Teo K, Yeo TT (2017) Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ Case RepDoi. https:\/\/doi.org\/10.1136\/bcr-2017-220971","journal-title":"BMJ Case RepDoi"},{"issue":"3","key":"1188_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/jcem-59-3-463","volume":"59","author":"M Gen","year":"1984","unstructured":"Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long term administration of bromocriptine*. J Clin Endocrinol Metabol 59(3):463\u2013470. https:\/\/doi.org\/10.1210\/jcem-59-3-463","journal-title":"J Clin Endocrinol Metabol"},{"issue":"12","key":"1188_CR41","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1507\/endocrine1927.62.12_1336","volume":"62","author":"T Takahashi","year":"1986","unstructured":"Takahashi T, Kuwayama A, Katoh T, Kageyama N (1986) Histological changes and operative findings of pituitary adenomas after bromocriptine treatment. Nihon Naibunpi Gakkai Zasshi 62(12):1336\u20131351. doi:https:\/\/doi.org\/10.1507\/endocrine1927.62.12_1336","journal-title":"Nihon Naibunpi Gakkai Zasshi"},{"issue":"2","key":"1188_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1055\/s-0036-1592193","volume":"78","author":"CC Zygourakis","year":"2017","unstructured":"Zygourakis CC, Imber BS, Chen R et al (2017) Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg B Skull Base 78(2):125\u2013131. https:\/\/doi.org\/10.1055\/s-0036-1592193","journal-title":"J Neurol Surg B Skull Base"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01188-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01188-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01188-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T09:23:04Z","timestamp":1635240184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01188-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01188-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"16 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict(s) of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}}]}}